The company has received the Certificate of GMP Compliance from the representative European inspection authority, Health Products Regulatory Authority (HPRA), Ireland.
Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone
Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
Revenue from operations up 26% to Rs. 768 crores
The move will add new global talent to Cytel’s Strategic Consulting group
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
New material distribution will serve medical device and pharmaceutical packaging manufacturers.
Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy
Study achieves primary endpoint of radiographic progression-free survival
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
Subscribe To Our Newsletter & Stay Updated
